

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)



(10) International Publication Number
WO 2021/186169 A1

(51) International Patent Classification:

A61K 38/26 (2006.01) C07K 14/605 (2006.01)

(21) International Application Number:

PCT/GB2021/050661

(22) International Filing Date:

16 March 2021 (16.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2003764.4 16 March 2020 (16.03.2020) GB
2003766.9 16 March 2020 (16.03.2020) GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED**
[GB/GB]; Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(72) Inventors: **BROWN, Giles Albert**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **CONGREVE, Miles Stuart**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **SCULLY, Conor**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **PAUL, Rebecca**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **MU-TO, Susumu**; c/o Jitsubo CO., LTD., Life Science Research Center 4-1, 1-1-43, Suehiro-cho, Tsurumi, Yokohama, Kanagawa, 230-0045 (JP). **WADA, Hiroki**; c/o Jitsubo CO., LTD., Life Science Research Center 4-1, 1-1-43, Suehiro-cho, Tsurumi, Yokohama, Kanagawa, 230-0045 (JP). **NUKUI, Seiji**; c/o Jitsubo CO., LTD., Life Science

Research Center 4-1, 1-1-43, Suehiro-cho, Tsurumi, Yokohama, Kanagawa, 230-0045 (JP).

(74) Agent: **STRATAGEM INTELLECTUAL PROPERTY MANAGEMENT LIMITED**; Meridian Court, Comberton Road, Cambridge Cambridgeshire CB23 2RY (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

(54) Title: ORAL GLP RECEPTOR AGONISTS



(1a),



(1b)

(57) Abstract: The disclosures herein relate to novel compounds of formula (1a) or formula (1b): and salts thereof, wherein S, T, W, Z, AA¹, AA², AA³, AA⁴, AA⁵, AA⁶, AA⁷, AA⁸, AA⁹, AA¹⁰, AA¹¹, AA¹², AA¹³, AA¹⁴, AA¹⁵, AA¹⁶, AA¹⁷, AA¹⁸, AA¹⁹, AA²⁰, AA²¹, AA²², S^a, T^a, W^a, X^a, Y^a, Z^a, AA^{1a}, AA^{2a}, AA^{3a}, AA^{4a}, AA^{5a}, AA^{6a}, AA^{7a}, AA^{8a}, AA^{9a}, AA^{10a}, AA^{11a}, AA^{12a}, AA^{13a}, AA^{14a}, AA^{15a}, AA^{16a}, R, R¹ and R² are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide (GLP) receptors.

WO 2021/186169 A1